Early detection is a key factor in patient fate. Currently, multiple biomolecules have been recognized as biomarkers. Nevertheless, their identification is only the starting line on the way to their implementation in disease diagnosis. Although blood is the biofluid par excellence for the quantification of biomarkers, its extraction is uncomfortable and painful for many patients. In this sense, there is a gap in which saliva emerges as a non-invasive and valuable source of information, as it contains many of the biomarkers found in blood. Recent technological advances have made it possible to detect and quantify biomarkers in saliva samples. However, there are opportunity areas in terms of cost and complexity, which could be solved using simpler methodologies such as those based on enzymes. Many reviews have focused on presenting the state-of-the-art in identifying biomarkers in saliva samples. However, just a few of them provide critical analysis of technical elements for biomarker quantification in enzymatic methods for large-scale clinical applications. Thus, this review proposes enzymatic assays as a cost-effective alternative to overcome the limitations of current methods for the quantification of biomarkers in saliva, highlighting the technical and operational considerations necessary for sampling, method development, optimization, and validation.

Recently, stem cell-based therapies have been proposed as an alternative for the treatment of many diseases. Stem cells (SCs) are well known for their capacity to preserve themselves, proliferate, and differentiate into multiple lineages. These characteristics allow stem cells to be a viable option for the treatment of diverse diseases. Traditional methodologies based on 2-dimensional culture techniques (T-flasks and Petri dishes) are simple and well standardized; however, they present disadvantages that limit the production of the cell yield required for regenerative medicine applications. Lately, microcarrier (MC)-based culture techniques have emerged as an attractive platform for expanding stem cells in suspension systems. Although the use of stem cell expansion on MCs has recently shown significant increase, their implementation for medical purposes is been hampered by bottlenecks in upstream and downstream processing. Therefore, there is an urgent need in the development of bioprocesses that simplify stem cell cultures under xeno-free conditions and detachment from MCs without diminishing their pluripotency and viability. A critical analysis of the factors that impact the up and downstream bioprocessing on MC-based stem cell cultures is presented in this review. This analysis aims to raise the awareness of the current drawbacks that limit MC-based stem cell bioprocessing in regenerative medicine and propose alternatives to overcome them.

During the past decade, stem cell transplantation has emerged as a novel therapeutic alternative for several diseases. Nevertheless, numerous challenges regarding the recovery and purification steps must be addressed to supply the number of cells required and in the degree of purity needed for clinical treatments. Currently, there is a wide range of methodologies available for stem cells isolation. Nevertheless, there is not a golden standard method that accomplishes all requirements. A desirable recovery method for stem cells has to guarantee high purity and should be sensitive, rapid, quantitative, scalable, non- or minimally invasive to preserve viability and differentiation capacity of the purified cells. In this context, aqueous two-phase systems (ATPS) represent a promising alternative to fulfill the mentioned requirements, promoting the use of stem cell-based therapies for incurable diseases. This practical review focuses on presenting the bases for the development of a novel and scalable bioprocess for the purification of stem cells, with a case scenario of CD133⁺ cells. The bioengineering strategies include the application of immunoaffinity ATPS in its multiple variants, including antibody-polymer conjugation, antibody addition and antibody immobilization. Conclusions are drawn in the light of the potential generic implementation of these strategies as an initial step in the establishment of bioprocesses for the purification of stem cells.